GammaKnife versus VMAT radiosurgery plan quality for many brain metastases.
GammaKnife versus VMAT radiosurgery plan quality for many brain metastases. J Appl Clin Med Phys. 2018 Oct 04;: Authors: Potrebko PS, Keller A, All S, Sejpal S, Pepe J, Saigal K, Kandula S, Sensakovic WF, Shridhar R, Poleszczuk J, Biagioli M Abstract The purpose of this work was to compare dose distributions between two radiosurgery modalities, single-isocenter volumetric modulated arc therapy (VMAT), and GammaKnife Perfexion (GK), in the treatment of a large number (≥7) of brain metastases. Twelve patients with 103 brain metastases were analyzed. The median number of targets per patient was 8 (range: 7-14). GK plans were compared to noncoplanar VMAT plans using both 6-MV flattening filter-free (FFF) and 10-MV FFF modes. Parameters analyzed included radiation therapy oncology group conformity index (CI), 12, 6, and 3 Gy isodose volumes (V12 Gy, V6 Gy, V3 Gy), mean and maximum hippocampal dose, and maximum skin dose. There were statistically significant differences in CI (2.5 ± 1.6 vs 1.6 ± 0.8 and 1.7 ± 0.9, P
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Conclusion: PSCCT is a rare but aggressive malignancy of the head and neck. Histopathologic and immunohistochemical evaluations are essential for diagnosis. While locoregional surgery and radiation therapy may improve the length of survival, the prognosis of patients with PSCCT is poor. Physicians should be mindful of this unique but deadly disease process, as early diagnosis and rapid treatment initiation are essential to optimize treatment outcomes. PMID: 31528145 [PubMed]
Radiation oncology firm Accuray has published an informational guide to help...Read more on AuntMinnie.comRelated Reading: Accuray to unveil system upgrades at ASTRO 2019 Accuray brings Radixact to Penn. Accuray posts higher sales in Q4 Accuray moves forward with China joint venture Accuray adds motion feature to radiation therapy system
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Just one high dose of radiation to the heart can significantly reduce episodes...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
A computer model accurately predicted two common toxicities associated with radiation therapy for head and neck cancer.Medscape Medical News
Based on multidisciplinary discussions with colleagues from breast surgical oncology, medical oncology, and plastic surgery, our recommendation was to proceed with local excision and sentinel lymph node biopsy followed by comprehensive radiation therapy to the chest wall and undissected regional nodal basins. Surgical pathology demonstrated invasive ductal carcinoma with 1.2 cm of residual disease and 30% tumor cell viability, negative margins, and no lymphovascular invasion. A sentinel lymph node biopsy was attempted, but no sentinel node was identified.
The challenge in treating malignant brain neoplasms lies in eradicating tumor while minimizing treatment-related damage to normal adjacent brain. These tumors are currently treated with conventional radiation therapy techniques, which control the tumor but are associated with considerable side effects. Synchrotron generated micro-beam radiation therapy (SMBRT) has shown promising results in preserving brain architecture while killing tumor cells, however physical characteristics of SMBRT limit its use.
Localized prostate cancer (PCa) has a high cure rate of 95.5%. PCa patients receive radiation therapy (RT) as a standard of care treatment. However, the major concern is the treatment-related side effects compromising the quality of life (QoL) in PCa patients. Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible late side effect of RT, that develops in more than half of PCa patients. There is no FDA approved drug to treat RiED. Phosphodiesterase type 5 inhibitors (PDE5i) are the most common pharmacological agents being used to treat RiED.